webwire.com
/1 week ago
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achiev...
- - • Data from the head-to-head study show efdoralprin alfa normalized and maintained functional AAT levels in people living with alpha-1 antitrypsin deficiency - • Efdoralpr...